Survival analysis of 68 HPV related oropharyngeal squamous cell carcinoma based on the new clinical staging system

doi:10.19438/j.cjoms.2021.03.011

Abstract

Abstract: PURPOSE: To compare the detection rate of human papillomavirus (HIV) associated oropharyngeal squamous cell carcinoma (SCC) with 3 methods, including brush cytology of oropharynx, P16 immunohistochemistry (IHC) and HPV polymerase chain reaction (PCR), evaluate the prognosis of patients with HPV positive based on the new and old TNM staging system, in order to provide clinical evidence to guide the precise diagnosis and treatment of HPV-related oropharyngeal SCC. METHODS: The results of brush cytology, P16 IHC and PCR in 171 patients with oropharyngeal SCC were analyzed and compared. The clinical and pathological data of 68 patients with HPV associated oropharyngeal SCC were collected,according to the new and old TNM staging system, the degradation situation was determined, the survival rate of patients at each stage, and the prognosis of patients with the new and old TNM stages was analyzed with SPSS 22.0 software package. RESULTS: The positive rates of HPV detected by P16 IHC, brush cytology and PCR were 25.7%, 14.6% and 24.0%, respectively. There was significant difference between brush cytology and other two methods (P =0.000), but there was no significant difference between IHC and PCR (P=0.205). Sixty-eight patients with HPV positive oropharyngeal SCC were classified according to the 7th and 8th edition of TNM staging system, they were 3 and 42 in stage Ⅰ, 7 and 14 in stage Ⅱ, 17 and 9 in stage Ⅲ, and 41 and 3 in stage Ⅳ, respectively. The 3-year survival rates of patients in the 7th and 8th edition of staging system was compared, stage Ⅰ was 100.0% and 89.7%(P=0.672), stage Ⅱ was 68.6% and 61.9% (P=0.961), stage Ⅲ was 66.8% and 37.0% (P=0.043), IV stage was 74.8% and 0.00% (P=0.000), respectively. The survival rates of early stage patients (stagesⅠandⅡ) in the 7th and 8th edition of staging system were 78.8% and 82.7% (P=0.585), and the survival rates of advanced patients (stage Ⅲ and Ⅳ) were 71.2% and 27.8% (P=0.000), respectively. According to the 7th edition of staging system of HPV positive patients, the survival rates of early and late patients were 78.8% and 71.2% (P=0.982). According to the 8th edition of staging system, the survival rates of early and late patients were 82.7% and 27.8%, respectively (P=0.000). CONCLUSIONS: Brush cytology test should not be used as a standard for the diagnosis of HPV positive oropharyngeal SCC. P16 IHC and PCR have their advantages and disadvantages, and should be selected according to the individual situation. For patients with HPV positive oropharyngeal SCC, the new staging system is more consistent with the actual clinical situation, the prognostic stratification is clearer, and it can better guide clinical decision-making and is worthy of clinical application

Key words: Oropharyngeal carcinoma, HPV, P16 IHC, HPV-RNA PCR, Brush cytology, TNM staging, Survival rate

CLC Number:

RT39.8

KONG Yu, YANG Xiao-chen, TAO Yue-qin, ZHOU Kai, LIN Zhi-hao, HOU Feng, FENG Yuan-yong, CHEN Yun-qing, JIANG Yan-xia, SONG Kai, SHANG Wei. Survival analysis of 68 HPV related oropharyngeal squamous cell carcinoma based on the new clinical staging system[J]. China Journal of Oral and Maxillofacial Surgery, 2021, 19(3): 238-243.

References

[1] Syrjänen K, Syrjänen S, Lamberg M, et al.Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis[J]. Int J Oral Surg, 1983, 12(6): 418-424.
[2] 胡凤玲, 余优成. 人乳头瘤病毒(HPV)与口咽癌相关性的研究进展[J]. 复旦学报(医学版), 2013, 40(4): 482-485.
[3] Elrefaey S, Massaro MA, Chiocca S, et al.HPV in oropharyngeal cancer: the basics to know in clinical practice[J]. Acta Otorhinolaryngol Ital, 2014, 34(5): 299-309.
[4] Goldenberg D, Begum S, Westra WH, et al.Cystic lymph node metastasis in patients with head and neck cancer: An HPV-associated phenomenon[J]. Head Neck, 2010, 30(7): 898-903.
[5] Yasui T, Morii E, Yamamoto Y, et al.Human papillomavirus and cystic node metastasis in oropharyngeal cancer and cancer of unknown primary origin[J]. PLoS One, 2014, 9(4): e95364.
[6] Chaturvedi AK, Engels EA, Pfeiffer RM, et al.Human papillomavirus and rising oropharyngeal cancer incidence in the United States[J]. J Clin Oncol, 2011, 29(32): 4294-4301.
[7] Van Dyne EA, Henley SJ, Saraiya M, et al.Trends in human papillomavirus-associated cancers-United States, 1999-2015[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(33): 918-924.
[8] Jemal A, Simard EP, Dorell C, et al.Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels[J]. J Natl Cancer Inst, 2013, 105(3): 175-201.
[9] Klaes R, Friedrich T, SPitkovsky D, et al.Overexpression of P16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri[J]. Int J Cancer, 2001, 92(2): 276-284.
[10] 尚伟, 郑家伟. 口腔及口咽癌新版TNM分期与NCCN诊治指南部分解读[J]. 中国口腔颌面外科杂志, 2018, 16(6): 533-546.
[11] 韩延敏, 邓娅. 液基细胞学检查联合高危型HPV检测在宫颈癌筛查中的临床应用[J]. 中国社区医师:医学专业, 2014, 12(12): 113-114.
[12] El-Naggar AK, Westra WH.P16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency[J]. Head Neck, 2012, 34(4): 459-461.
[13] Ang KK, Harris J, Wheeler R, et al.Human papillomavirus and survival of patients with oropharyngeal cancer[J]. N Engl J Med, 2010, 363(1): 24-35.
[14] Maruyama H, Yasui T, Ishikawa-Fujiwara T, et al.Human papillomavirus and p53 mutations in head and neck squamous cell carcinoma among Japanese population[J]. Cancer Sci, 2014, 105(4): 409-417.